TB-500 (10mg)

Description

What is TB‑500?

TB‑500 is a synthetic peptide derived from the naturally occurring 43‑amino‑acid protein Thymosin beta‑4 (Tβ4). It contains the central actin‑binding motif (LKKTETQ) and is widely used in preclinical tissue‑repair, cardiac‑recovery, and wound‑healing research models. It is distinct from the full‑length Tβ4 biologic used in some clinical trials (Regenerx RGN‑259, RGN‑352).

Mechanism of Action

• Sequesters G‑actin and regulates the actin cytoskeleton during cell migration and wound closure
• Upregulates VEGF‑driven angiogenesis in ischemic tissue models
• Downregulates pro‑inflammatory cytokines (TNF‑α, IL‑1β) and upregulates laminin‑5 and MMPs involved in remodeling
• Promotes endothelial‑cell and epicardial‑progenitor migration in cardiac repair models

Compound Properties

• Molecular formula: C₇₈H₁₃₄N₂₂O₂₆
• Molecular weight: ~1814.07 g/mol (for the 17‑aa active fragment)
• CAS: 77591‑33‑4 (parent Tβ4 sequence)
• Sequence (17‑aa fragment): Ac‑LKKTETQ‑EKNPLPSKETIEQEKQ (synthetic variant)
• Form: Lyophilized powder
• Unit size: 10 mg / vial
• Source: Solid‑phase peptide synthesis; ≥98% purity by HPLC

Research‑Reference Dosing

Published research‑reference ranges in preclinical and veterinary literature:

• Malinda et al., Journal of Investigative Dermatology (1999): Tβ4 accelerated dermal wound closure in rodent models.
• Bock‑Marquette et al., Nature (2004): Tβ4 improved cardiac function after infarct in mice.
• Carrion et al., Journal of Equine Veterinary Science: reports on TB‑500 in equine soft‑tissue injury (veterinary).
• Human efficacy data for the TB‑500 fragment specifically is sparse; most translational data exists for full‑length Tβ4 (RGN‑259, RGN‑352) in ophthalmic and cardiac trials.

Research Findings

• Accelerated wound closure, angiogenesis, and reduced inflammation in rodent skin and cardiac models (Malinda 1999; Bock‑Marquette 2004)
• Veterinary use in equine tendon and ligament injury reported
• Full‑length Tβ4 reached Phase 3 in dry‑eye (RGN‑259) with favorable safety profile; extrapolation to the 17‑aa fragment is not established

Known Side Effects Reported in Research/Trials

• Injection‑site reactions
• Fatigue, transient lightheadedness reported anecdotally
• Theoretical concern: angiogenesis promotion may be contraindicated in the presence of occult neoplasia (has not been rigorously characterized in humans)
• Long‑term human safety data for the fragment is unavailable

Storage & Handling

• Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
• After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
• Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.

Certificate of Analysis

A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.

Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.